Acquisition Creates Industry-Leading Portfolio of Catheter Securement Solutions

BETHLEHEM, Pa. , Sept. 27, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, announced today it has acquired the innovative Clik-FIX catheter securement device portfolio from Starboard Medical, Inc. B. Braun's acquisition builds on the company's history of product and program innovation to improve the patient experience and outcomes with peripheral intravenous (IV) therapy.

Designed with patient care in mind, the Clik-FIX portfolio acquisition includes the following:

Clik-FIX Peripheral catheter securement device is an all-in-one integrated securement device with bio-occlusive dressing. This device replaces the need to use individual tape, gauze and transparent dressings.

Clik-FIX PICC/Central catheter securement device is a universal device designed to secure most peripherally inserted central catheters (PICC) and central catheters with an active dual locking mechanism. Clik-FIX is an effective alternative to sutures, tape, tape-based stabilization and other securement systems.

Clik-FIX Universal catheter securement device is designed to stabilize and secure any medical tubing junction with a Luer lock connection.

Clik-FIX Neonatal PICC catheter securement device features a universal design and is compatible with most neonatal PICC lines. It features a soft foam securement base with no hard plastic parts to cause pressure, bruising or trauma to a baby's skin.

Clik-FIX Soft PICC/Central securement device features a soft foam securement base with no hard plastic parts to cause pressure, bruising or trauma to the skin. Its universal design is compatible with most PICC and central lines.

"Improving the standard of care for patients is at the heart of all we do at B. Braun," said Jean-Claude Dubacher , Chairman and Chief Executive Officer, B. Braun Medical Inc. "The addition of the innovative Clik-FIX portfolio combined with our expertise and commercial capabilities ensures we will continue to meet our customers' evolving needs and extend our position as a leader in IV therapy," he added.

Starboard Medical is a woman co-owned medical device company focused on delivering superior medical devices that enhance patient care and improve patient outcomes.

"Clik-FIX devices were the result of a personal experience with an improperly secured IV catheter," said Kerry Edgar , President, Starboard Medical, Inc. "We're pleased that B. Braun, with its commercial capabilities and long history of IV therapy expertise, will bring the Clik-FIX device portfolio to more clinicians and more patients around the world."

Peripheral Vascular Access is the Most Common Invasive Procedure Performed in Healthcare

It is estimated that 380 million PIVCs are sold in the United States annually.1 In fact, hospital patients are more likely to get an IV than any other device, as over 80% of patients do.2

In hospitals today, 30.2% of PICC lines3 and up to 69% of PIVCs inserted fail.4 Collectively, this can lead to serious implications for patients, including increased length of stay and costs.5 Catheter stabilization has become a central means to improve outcomes.5

"Catheter securement is critical in proper stabilization to avoid potentially serious issues for patients," said Patrick Evangelista, RN , BSN, MSN, VA-BC. "Clik-FIX is a proven catheter securement platform that I use in my everyday practice, and its technical performance is demonstrated in my poster published at AVA 2022".

As a leader in infusion therapy, B. Braun is committed to raising the bar for patient care by delivering innovative products and programs that include clinical education and data collection. B. Braun has partnered with the Association for Vascular Access in a long-term collaboration to advance education and training on IV placement. Additionally, B. Braun created the Peripheral Advantage® Program, which is designed to improve patients' experiences with peripheral IV therapy. This comprehensive program, available to any hospital in the U.S., combines clinical instruction, data-driven insights and advanced tools to empower nurses to achieve first-stick success and help prevent many of the complications associated with peripheral IV therapy.

B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. The company employs 8,500 people at over 30 locations across North America .

Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website.

iData Research. (2020). US Market Report Suite for Vascular Access Devices and Accessories

Rivera AM, Strauss KW, van Zundert AA, Mortier EP. Matching the peripheral intravenous catheter to the individual patient. Acta Anaesthesiol Belg. 2007;58(1):19-25.

Grau D, Clarivet B, Lotthé A, Bommart S, Parer S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017;6:18. Published 2017 Jan

Cooke, M., Ullman, A., Ray-Barruel, G., Wallis, M., Corley, A., Rickard, C. (2018). Not "just" an intravenous line: Consumer perspectives on peripheral intravenous cannulation (PIVC).  An international cross-sectional survey of 25 countries.  Plos One.  https://doi.org/10.1371/journal.pone.0193436

Helm RE, Klausner JD, Klemperer JD, FLint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015 May-Jun;38(3):189-203. doi: 10.1097/NAN.0000000000000100. PMID: 25871866.

View original content to download multimedia:https://www.prnewswire.com/news-releases/b-braun-acquires-clik-fix-catheter-securement-devices-from-starboard-medical-301633531.html

SOURCE B. Braun Medical Inc.

Investors are facing a storm of headwinds right now – a genuine bear market, stubbornly high inflation, rising interest rates, and increased fears of a recession in the near-term. However, Mary Callahan Erdoes, CEO of JPMorgan's Asset & Wealth Management division, advises investors to stay invested. "It's actually the easiest time in the world to find alpha — there is alpha everywhere... It's everywhere, because we are in such a state of change... While all the world is focused on all the black

The cuts are intended to reduce costs, streamline operations and increase profitability for BioMarin, frequently tapped as a likely takeover target.

Cannabis stocks dropped Friday after President Joe Biden on Thursday announced pardons for thousands of people convicted of marijuana possession under federal law. The president called on governors to take similar action for state offenses. Biden also said his administration will review whether cannabis should remain in its current federal category along with heroin and LSD — a move widely...

While CommonSpirit Health confirmed it experienced an “IT security issue” earlier this week, the company has remained mum when pressed for more details about the scope of the attack. The health system giant has 140 hospitals in 21 states. In Tacoma, Washington, Mark Kellogg told KING-TV that his wife, Kathy, had been scheduled to get a cancerous tumor on her tongue removed on Monday, but the procedure was put off several days because of the cyberattack.

Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.

The CDC's latest report on COVID-19 vaccinations didn't provide enough fuel for shareholder optimism.

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

President Joe Biden has said the pandemic is over, despite more than 300 people dying from COVID-related illness every day. Now cruise lines, which experienced severe disruptions during the early days of the COVID-19 outbreak and, in some cases were stranded offshore due to ports refusing them permission to dock due to coronavirus outbreaks onboard, are relaxing their health protocols. Harry Sommer, chief executive of Norwegian Cruise Line  cited “significant, positive progress in the public-health environment.”

Since COVID-19 began to spread two and a half years ago, our understanding of the virus has changed drastically. However, that isn't to say that the ever-adapting pathogen hasn't kept the medical community on its toes. New highly contagious subvariants have made it more difficult for our bodies to defend against the virus while also changing up the likelihood of which symptoms you'll feel when you come down with it. In fact, new data now shows that even running a fever isn't as common as experie

The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

Medicare recipients will get a financial boost in 2023 after the Centers for Medicare and Medicaid Services announced lower premiums across several plans. Social Security: Women Get $354 Per Month...

Novocure (NASDAQ: NVCR) stands out as a great example and is attractively valued right now. TTFields use electric fields that are tuned to specific frequencies to interfere with the division of cancer cells. Novocure has already demonstrated that TTFields work well in treating glioblastoma multiforme (GBM), an aggressive form of brain cancer.

European Union agency Eurofound's surveys of 200,000 people found that those reporting "bad" or "very bad" mental health doubled from 6.4% in March 2020 at the onset of the crisis to 12.7% two years later even as restrictions were eased. The online surveys, from March 2020 to May 2022, also revealed that more people across the 27 EU nations are struggling to make ends meet and at greater risk of energy poverty, in particular due to high inflation. Some 53% of respondents reported that their household had difficulties making ends meet in Spring 2022, compared to 47% at the start of the pandemic, Eurofound said in a separate report.

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics announced data from two real-world evidence studies evaluating Lagevrio (molnupiravir), an investigational oral antiviral COVID-19 medicine. According to the results of a pivotal clinical trial in the U.K., Merck’s COVID-19 antiviral pill failed to show it can lower the risks of hospitalization and death among adults at higher risk from the disease. Preliminary results from a trial of more than 25,000 people show that taking molnupiravir c

There are early signs that COVID infections and reinfections are leading to more life-threatening conditions, says physician and author Carolyn Barber.

"Because they caught it early, very little damage had been done and she’s doing really well."View Entire Post ›

The shift comes as federal health officials are bracing for a renewed wave of COVID-19 infections this fall and winter.

Becton Dickinson’s recall applies to 17 versions of reusable metal containers under the Genesis Sterrad brand after potential breaches were found.

If you want to burn fat, should you do cardio or lift weights? Experts weigh in on the benefits of cardio and strength training for weight loss.